A study of 22 patients with advanced NSCLC, breast, or bladder cancer, demonstrated heterogenous [89Zr]atezolizumab uptake, SUVmax measured with PET/CT, within and between patients, and uptake above the mean was associated with improved progression free and overall survival with anti-PD-L1 therapy [24]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.